Search results for "B1"

showing 10 items of 1109 documents

Development of an Antifungal Device Based on Oriental Mustard Flour to Prevent Fungal Growth and Aflatoxin B1 Production in Almonds

2021

The present study describes the manufacture of an antifungal device composed of oriental mustard flour and hydroxyethyl-cellulose (H-OMF) and evaluates its efficacity in inhibiting Aspergillus flavus growth and aflatoxin B1 (AFB1) production in almonds. Additionally, it compares the H-OMF with allyl isothiocyanate (AITC) and a freeze-dried extract of yellow mustard flour (YMF-E); such substances were previously described as antifungal. Minimum inhibitory concentration (MIC), Minimum fungicidal concentration (MFC), the H-OMF in vitro antifungal activity, and the residual fungal population, as well as the production of AFB1 in almonds were determined. AITC and YMF-E showed significant antifun…

Aflatoxin B1Health Toxicology and Mutagenesishydroxyethyl-cellulose-based deviceFlourRfood and beveragesToxicologynatural antimicrobialsPrunus dulcisArticleFungicides IndustrialAITCfood safetymycotoxinsnatural antimicrobials; fungi; mycotoxins; food safety; AITC; <i>Aspergillus flavus</i>; hydroxyethyl-cellulose-based deviceMedicinefungi<i>Aspergillus flavus</i>Aspergillus flavusMustard PlantPlant DiseasesToxins
researchProduct

Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1.

2006

The hepatic carcinogen aflatoxin B1 (AFB1) is metabolized in the liver by at least four different P450s, all of which exhibit large interindividual differences in the expression levels. These differences could affect the individual risk of hepatocellular carcinoma (HCC). We investigated the metabolism of AFB1 in a panel of 13 human liver microsomal preparations using a hepatic abundance model, which takes into account the specific kinetic parameters and the expression levels of these P450s. We found a 12-fold variability in the production rate of the carcinogenic metabolite AFB1-8,9-epoxide (AFBO) and a 22-fold variability in the production of the detoxification product AFQ1. The ratio betw…

AflatoxinAflatoxin B1MetabolitePharmacologyToxicology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCytochrome P-450 Enzyme SystemmedicineCytochrome P-450 CYP3AHumansCarcinogenBiotransformationChromatography High Pressure Liquid030304 developmental biologychemistry.chemical_classification0303 health sciencesPrimary metaboliteGeneral MedicineMetabolismmedicine.diseaseEnzymeBiochemistrychemistryLiver030220 oncology & carcinogenesisHepatocellular carcinomaMicrosomeCarcinogensChemical research in toxicology
researchProduct

High Pressure Processing Impact on Alternariol and Aflatoxins of Grape Juice and Fruit Juice-Milk Based Beverages.

2021

High-pressure processing (HPP) has emerged over the last 2 decades as a good alternative to traditional thermal treatment for food safety and shelf-life extension, supplying foods with similar characteristics to those of fresh products. Currently, HPP has also been proposed as a useful tool to reduce food contaminants, such as pesticides and mycotoxins. The aim of the present study is to explore the effect of HPP technology at 600 MPa during 5 min at room temperature on alternariol (AOH) and aflatoxin B1 (AFB1) mycotoxins reduction in different juice models. The effect of HPP has also been compared with a thermal treatment performed at 90 °C during 21 s. For this, different juice models, or…

AflatoxinFood industryFood HandlingLiquid Phase MicroextractionAlternariolPharmaceutical ScienceOrganic chemistryFood Contamination01 natural sciencesArticlealternariolAnalytical ChemistryPascalizationBeverageschemistry.chemical_compoundLactones0404 agricultural biotechnologyQD241-441AflatoxinsTandem Mass Spectrometryjuice modelsDrug Discoverydispersive liquid–liquid microextractionAnimalsVitisFood sciencePhysical and Theoretical ChemistryMycotoxinChromatography High Pressure LiquidOrange juicehigh-pressure processingbusiness.industry010401 analytical chemistry04 agricultural and veterinary sciencesMycotoxinsFood safety040401 food science0104 chemical sciencesFruit and Vegetable JuicesMilkchemistryChemistry (miscellaneous)Fruitaflatoxin B1Molecular Medicinebusinessliquid chromatography coupled to tandem mass spectrometryFood contaminantMolecules (Basel, Switzerland)
researchProduct

Occurrence of aflatoxins in feedstuff, sheep milk and dairy products in Western Sicily

2003

Samples of feedstuffs (15), milk (40), and cheese (30) coming from sheep and dairy farms (23) or market in WesternSicily were analyzed for their respective content of aflatoxin B1 (AFB1) and M1 (AFM1) to evidence any possible indirectmycotoxin contamination risk to the consumer. Analyses using HPLC and fluorescence detection were performed afterimmunoaffinity column sample extraction and cleanup; AFM1 was detected in 30% of the milk samples at levels rangingfrom 4 to 23 ng/l and in 13% of the cheeses from 21 to 101 ng/kg; in the feed the AFB1 ranged from None of the contaminated samples exceeded the legal limits set down by the European Union for milk (50 ng/l) and feed(5 &mu;g/kg ), or tha…

AflatoxinMycotoxin contamination010405 organic chemistry010401 analytical chemistryContaminationBiology01 natural sciences0104 chemical sciencesmedia_common.cataloged_instanceAnimal Science and ZoologyFood sciencelcsh:Animal cultureSample extractionEuropean unionSheep milkAflatoxin M1 Sheep milk Sheep cheese Aflatoxin B1 Feedstuffmedia_commonlcsh:SF1-1100Italian Journal of Animal Science
researchProduct

A53T-Alpha-Synuclein Overexpression Impairs Dopamine Signaling and Striatal Synaptic Plasticity in Old Mice

2010

BACKGROUND: Parkinson's disease (PD), the second most frequent neurodegenerative disorder at old age, can be caused by elevated expression or the A53T missense mutation of the presynaptic protein alpha-synuclein (SNCA). PD is characterized pathologically by the preferential vulnerability of the dopaminergic nigrostriatal projection neurons. METHODOLOGY/PRINCIPAL FINDINGS: Here, we used two mouse lines overexpressing human A53T-SNCA and studied striatal dysfunction in the absence of neurodegeneration to understand early disease mechanisms. To characterize the progression, we employed young adult as well as old mice. Analysis of striatal neurotransmitter content demonstrated that dopamine (DA…

AgingDopaminelcsh:MedicineMicechemistry.chemical_compoundHomer Scaffolding ProteinsReceptor Cannabinoid CB1lcsh:ScienceLong-term depressionNeurotransmitterChromatography High Pressure LiquidIn Situ Hybridization FluorescenceOligonucleotide Array Sequence AnalysisMice KnockoutNeuronal PlasticityMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionDopaminergicNeurodegenerationGenetics and Genomics/Gene ExpressionElectrophysiologyalpha-SynucleinResearch ArticleRadioimmunoprecipitation Assaymedicine.medical_specialtyNeuronal Calcium-Sensor ProteinsHOMER1Substantia nigraNeurotransmissionBiologyNeurological DisordersInternal medicinemedicineAnimalsHumansddc:610Cyclic Nucleotide Phosphodiesterases Type 7Activating Transcription Factor 2lcsh:RNeuropeptidesmedicine.diseaseMolecular biologyCorpus StriatumMice Mutant StrainsEndocrinologyGenetics and Genomics/Disease ModelschemistrySynaptic plasticitylcsh:QCarrier ProteinsPLoS ONE
researchProduct

Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid de…

2012

Alzheimer's disease (AD) is characterized by amyloid-beta deposition in amyloid plaques, neurofibrillary tangles, inflammation, neuronal loss, and cognitive deficits. Cannabinoids display neuromodulatory and neuroprotective effects and affect memory acquisition. Here, we studied the impact of cannabinoid receptor type 1 (CB1) deficiency on the development of AD pathology by breeding amyloid precursor protein (APP) Swedish mutant mice (APP23), an AD animal model, with CB1-deficient mice. In addition to the lower body weight of APP23/CB1(-/-) mice, most of these mice died at an age before typical AD-associated changes become apparent. The surviving mice showed a reduced amount of APP and its …

Agingmedicine.medical_specialtyPathologyCannabinoid receptormedicine.medical_treatmentMutantMice TransgenicInflammationDiseaseNeuroprotectionAmyloid beta-Protein PrecursorMiceReceptor Cannabinoid CB1Alzheimer DiseaseCell Line TumorInternal medicinemental disordersmedicineAmyloid precursor proteinAnimalsHumansMaze LearningCognitive impairmentAmyloid beta-Peptidesbiologybusiness.industryGeneral NeuroscienceBody WeightAge FactorsBrainPeptide FragmentsDisease Models AnimalEndocrinologyGene Expression RegulationMutationbiology.proteinlipids (amino acids peptides and proteins)MicrogliaNeurology (clinical)CannabinoidGeriatrics and Gerontologymedicine.symptomCognition DisordersbusinessDevelopmental BiologyNeurobiology of Aging
researchProduct

Cannabinoid and nitric oxide signaling interplay in the modulation of hippocampal hyperexcitability: study on electrophysiological and behavioral mod…

2015

A growing bulk of evidence suggests that cannabinoid system plays a pivotal role in the control of hyperexcitability phenomena. Notwithstanding, the anticonvulsant action of cannabinoids has not been fully addressed, in particular the involvement of potential cellular neuromodulators, for instance nitric oxide. In the current study, we focused on two distinct rat models of temporal lobe epilepsy, the Maximal Dentate Activation and the pilocarpine-induced acute seizures, providing both electrophysiological and behavioral data on cannabinoid and nitrergic system interplay. We evaluated the antiepileptic effects of WIN 55,212-2, (R)-(+)-[2,3-dihydro-5-methyl-3-(4- morpholinylmethyl) pyrrolo[1,…

AgonistAM251MaleCannabinoid receptorIndazolesmedicine.drug_classmedicine.medical_treatmentMorpholinesHippocampusPharmacologyNaphthalenesNitric OxideHippocampusSettore BIO/09 - FisiologiaEpilepsyPiperidinesReceptor Cannabinoid CB1medicineAnimalshippocampus temporal lobe epilepsy cannabinoids behavior percentage of protection electrophysiology.Rats WistarWIN 55212-2Cannabinoid Receptor AgonistsDose-Response Relationship DrugCannabinoidsGeneral NeurosciencePilocarpinemedicine.diseaseEndocannabinoid systemBenzoxazinesRatsDisease Models AnimalEpilepsy Temporal LobePyrazolesCannabinoidNitric Oxide SynthasePsychologyNeurosciencemedicine.drug
researchProduct

Evidences of cannabinoids-induced modulation of paroxysmal events in an experimental model of partial epilepsy in the rat.

2009

The anticonvulsant effect of cannabinoids (CB) has been shown to be mediated by the activation of the CB(1) receptor. This study evaluates the anticonvulsant activity of (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-Yl]-1-naphthalenylmethanone (WIN55,212-2, CB agonist) alone or preceded by the administration of N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251, selective CB(1) antagonist) in an experimental in vivo model of complex partial seizures (maximal dentate gyrus activation - MDA) in the rat. WIN55,212-2 (21mgkg(-1)) exerted an anticonvulsant effect, significantly reduced by the pre-treatme…

AgonistAM251Malemedicine.medical_specialtyCannabinoid receptormedicine.drug_classmedicine.medical_treatmentMorpholinesNaphthalenesSettore BIO/09 - FisiologiaEpilepsyPiperidinesReceptor Cannabinoid CB1Internal medicineControlCannabinoid Receptor ModulatorsmedicineAnimalsRats WistarReceptorEpilepsyChemistryCannabinoidsGeneral NeuroscienceAntagonistBrainmedicine.diseaseCalcium Channel BlockersElectric StimulationBenzoxazinesRatsDisease Models AnimalMaximal dentate activationAnticonvulsantEndocrinologySettore BIO/14 - FarmacologiaRatPyrazolesAnticonvulsantsCannabinoidEpilepsies Partialmedicine.drugNeuroscience letters
researchProduct

The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment.

2011

Background: Cannabinoids are known to reduce intestinal inflammation. Atypical cannabinoids produce pharmacological effects via unidentified targets. We were interested in whether the atypical cannabinoid O-1602, reportedly an agonist of the putative cannabinoid receptor GPR55, reduces disease severity of dextran sulfate sodium (DSS) and trinitrobenzene sulfonic acid (TNBS)-induced colitis in C57BL/6N and CD1 mice. Methods: DSS (2.5% and 4%) was supplied in drinking water for 1 week while TNBS (4 mg) was applied as a single intrarectal bolus. Results: Both treatments caused severe colitis. Injection of O-1602 (5 mg/kg intraperitoneally) significantly reduced macroscopic and histological col…

AgonistMaleCannabinoid receptormedicine.drug_classColonNeutrophilsmedicine.medical_treatmentPharmacologyMotor ActivityInflammatory bowel diseaseArticleReceptors G-Protein-CoupledReceptor Cannabinoid CB2chemistry.chemical_compoundMiceReceptor Cannabinoid CB1CyclohexanesmedicineImmunology and AllergyAnimalsCannabidiolColitisReceptorReceptors CannabinoidPeroxidaseMice KnockoutAnalysis of VarianceO-1602business.industryCannabinoidsDextran SulfateGastroenterologyResorcinolsmedicine.diseaseColitisMice Inbred C57BLChemotaxis LeukocyteDisease Models AnimalchemistryGPR55Neutrophil InfiltrationTrinitrobenzenesulfonic AcidImmunologylipids (amino acids peptides and proteins)CannabinoidbusinessInflammatory bowel diseases
researchProduct

Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission

2012

Biphasic effects of cannabinoids have been shown in processes such as feeding behavior, motor activity, motivational processes and anxiety responses. Using two different tests for the characterization of anxiety-related behavior (elevated plus-maze and holeboard), we first identified in wild-type C57BL/6N mice, two doses of the synthetic CB1 cannabinoid receptor agonist CP-55,940 with anxiolytic (1 mug/kg) and anxiogenic properties (50 mug/kg), respectively. To clarify the role of CB1 receptors in this biphasic effect, both doses were applied to two different conditional CB1 receptor knockout (KO) mouse lines, GABA-CB1-KO (CB1 receptor inactivation in forebrain GABAergic neurons) and Glu-CB…

AgonistMaleCannabinoid receptormedicine.drug_classmedicine.medical_treatmentGlutamic AcidCyclopentanesPharmacologyGABAB receptorBiologyAnxietyMotor ActivityAnxiolyticSynaptic TransmissionGlutamatergicMiceReceptor Cannabinoid CB1medicineAnimalsGABA Agonistsgamma-Aminobutyric AcidPharmacologyMice KnockoutBehavior AnimalDose-Response Relationship DrugCannabinoidsfood and beveragesCyclohexanolsMice Inbred C57BLPsychiatry and Mental healthPyrimidinesAnxiogenicnervous systemReceptors GABA-BGABAergiclipids (amino acids peptides and proteins)Original ArticleCannabinoidpsychological phenomena and processes
researchProduct